Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)

被引：1
|
作者：
Perez
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 20期
关键词：
D O I：
10.1200/JCO.2017.74.3971
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2342 / 2342
页数：1
相关论文
共 50 条
  • [1] Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2 Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study (vol 35, pg 141, 2017)
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04) : 358 - 358
  • [2] Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
    Perez, Edith A.
    Barrios, Carlos
    Eiermann, Wolfgang
    Toi, Masakazu
    Im, Young-Hyuck
    Conte, Pierfranco
    Martin, Miguel
    Pienkowski, Tadeusz
    Pivot, Xavier
    Burris, Howard, III
    Petersen, Jennifer A.
    Stanzel, Sven
    Strasak, Alexander
    Patre, Monika
    Ellis, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (02) : 141 - +
  • [3] Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE
    Perez, Edith A.
    Barrios, Carlos
    Eiermann, Wolfgang
    Toi, Masakazu
    Im, Young-Hyuck
    Conte, Pierfranco
    Martin, Miguel
    Pienkowski, Tadeusz
    Pivot, Xavier B.
    Burris, Howard A., III
    Petersen, Jennifer A.
    De Haas, Sanne
    Hoersch, Silke
    Patre, Monika
    Ellis, Paul Anthony
    CANCER, 2019, 125 (22) : 3974 - 3984
  • [4] Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study
    Krop, Ian E.
    Im, Seock-Ah
    Barrios, Carlos
    Bonnefoi, Herve
    Gralow, Julie
    Toi, Masakazu
    Ellis, Paul A.
    Gianni, Luca
    Swain, Sandra M.
    Im, Young-Hyuck
    De Laurentiis, Michelino
    Nowecki, Zbigniew
    Huang, Chiun-Sheng
    Fehrenbacher, Louis
    Ito, Yoshinori
    Shah, Jigna
    Boulet, Thomas
    Liu, Haiying
    Macharia, Harrison
    Trask, Peter
    Song, Chunyan
    Winer, Eric P.
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (05) : 438 - +
  • [5] Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer
    Van den Mooter, Tom
    Teuwen, Laure-Anne
    Rutten, Annemie
    Dirix, Luc
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (05) : 749 - 760
  • [6] Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
    Edith A. Perez
    Sanne Lysbet de Haas
    Wolfgang Eiermann
    Carlos H. Barrios
    Masakazu Toi
    Young-Hyuck Im
    Pier Franco Conte
    Miguel Martin
    Tadeusz Pienkowski
    Xavier B. Pivot
    Howard A. Burris
    Sven Stanzel
    Monika Patre
    Paul Anthony Ellis
    BMC Cancer, 19
  • [7] Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
    Perez, Edith A.
    de Haas, Sanne Lysbet
    Eiermann, Wolfgang
    Barrios, Carlos H.
    Toi, Masakazu
    Im, Young-Hyuck
    Conte, Pier Franco
    Martin, Miguel
    Pienkowski, Tadeusz
    Pivot, Xavier B.
    Burris, Howard A., III
    Stanzel, Sven
    Patre, Monika
    Ellis, Paul Anthony
    BMC CANCER, 2019, 19 (1)
  • [8] Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
    Hurvitz, Sara A.
    Dirix, Luc
    Kocsis, Judit
    Bianchi, Giulia V.
    Lu, Janice
    Vinholes, Jeferson
    Guardino, Ellie
    Song, Chunyan
    Tong, Barbara
    Ng, Vivian
    Chu, Yu-Waye
    Perez, Edith A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (09) : 1157 - 1163
  • [9] Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
    Edith A. Perez
    Sanne Lysbet de Haas
    Wolfgang Eiermann
    Carlos H. Barrios
    Masakazu Toi
    Young-Hyuck Im
    Pier Franco Conte
    Miguel Martin
    Tadeusz Pienkowski
    Xavier B. Pivot
    Howard A. Burris
    Sven Stanzel
    Monika Patre
    Paul Anthony Ellis
    BMC Cancer, 19
  • [10] Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive, Locally Advanced, or Metastatic Breast Cancer
    Miller, Kathy D.
    Dieras, Veronique
    Harbeck, Nadia
    Andre, Fabrice
    Mahtani, Reshma L.
    Gianni, Luca
    Albain, Kathy S.
    Crivellari, Diana
    Fang, Liang
    Michelson, Glenn
    de Haas, Sanne L.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (14) : 1437 - +
12345